This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Diabetes-Drug Makers Face FDA Hurdle

Concern over reports that link diabetes drugs to heart trouble is compelling U.S. drug regulators to ask diabetes-drug makers for more safety data. These requests for additional data could delay new product approvals by years and add millions of dollars to development and post-market commitment costs.

The U.S. Food and Drug Administration is reportedly sending letters to all companies with diabetes drugs in development, informing them that the agency will now require safety data prior to approval that measures a drug's cardiovascular risk.

Companies reportedly receiving the FDA letters include Amylin Pharmaceuticals (AMLN), Vivus (VVUS - Get Report), Incyte Pharmaceuticals (INCY - Get Report) and Roche, according to sources familiar with the letters. All have diabetes drugs in mid- to late-stage clinical trials.

"It appears companies with drugs at the FDA -- Novo Nordisk (NVO - Get Report)(liraglutide), Takeda (alogliptin) and AstraZeneca (AZN - Get Report)/ Bristol-Myers Squibb (BMY - Get Report) (saxagliptin) -- have not yet received a letter, although discussions with industry participants lead us to believe they are coming," wrote Morgan Stanley biotech analyst Steve Harr in a note to clients on Friday. "The companies under review have the greatest uncertainty, and outcomes will impact these companies and competitors."

Novo Nordisk's drug, liraglutide, is expected to be discussed at an upcoming advisory panel meeting.

An FDA spokesperson would not comment on the letters, stating only that the agency is working on guidance on issues surrounding cardiovascular risk and diabetes drugs.

Research published in 2007 linked Avandia, a diabetes drug marketed by GlaxoSmithKline (GSK - Get Report), to an increased risk of heart attack in people with type 2 diabetes. Since then, the cardiovascular risk of all diabetes drugs has become a major concern for regulators both in Europe and the U.S.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
BMY $64.66 -1.70%
AZN $68.57 -2.00%
GSK $46.10 -2.30%
INCY $91.95 -2.40%
NVO $53.58 -2.00%

Markets

DOW 17,854.30 -122.01 -0.68%
S&P 500 2,077.30 -8.94 -0.43%
NASDAQ 4,923.7230 -23.7180 -0.48%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs